INACTIVE/DISSOLVED
Address
Excalibur Fund Managers Ltd
Berkeley Square
Berkeley Square House
London
W1J 6BD
United Kingdom
Phone
Industry
VCID: 32746
Profile
Corporate information
Official name
Excalibur Fund Managers Ltd
Registration country
Official name
Excalibur Fund Managers Ltd
Registration country
Investment activity status
Not investing
Funds managed
| Fund | Type | Vintage |
|---|---|---|
| Merlin Biosciences Fund III LP | Venture | 2003 |
Investments
Selected investments
| Company | Country | Notes | ||
|---|---|---|---|---|
|
Lab21 Ltd |
United Kingdom | N/A |
|
|
|
Ark Therapeutics Group PLC Gene-based drugs for vascular and circulatory diseases and cancer. IPO in March 2004. |
United Kingdom | N/A |
|
|
|
LiDCO Group PLC Researches, develops, manufactures and sells innovative medical devices. IPO in June 2004. |
United Kingdom | N/A |
|
|
|
Sosei Co Ltd Identifying new uses for established drugs. Arakis merged with Sosei Co in August 2005. |
Japan | N/A |
|
|
|
PIramed Pharma Ltd Oncology Therapeutics. Acquired by Roche in April 2008. |
United Kingdom | N/A |
|
|
|
Biovertis AG Hospital-acquired infections; respiratory tract infections; urinary tract infections. Acquired Morphochem AG in March 2006. |
Austria | N/A |
|
|
|
Neurotech Pharmaceuticals Inc Cell-based drugs for diseases of the eye. |
United States | N/A |
|
|
|
Vectura Group PLC Drug formulations and devices for respiratory diseases. IPO in July 2004. |
United Kingdom | N/A |
|
|
|
Plethora Solutions Holdings PLC Discovering and developing urological products. IPO in March 2005. |
United Kingdom | N/A |
|
|
|
Cambridge Biotechnology Ltd Small molecule drugs for pain and obesity. Aquired by Biovitrum AB in April 2005. |
United Kingdom | N/A |
|
|
|
Noxxon Pharma AG Mirror image oligonucleotide drugs. |
Germany | N/A |
|
|
|
Wilex AG Antibody and small molecule cancer therapies. IPO in November 2006 |
Germany | N/A |
|
|
|
Virgin Health Bank Ltd Cord blood banking. |
United Kingdom | N/A |
|
|
|
Cyclacel Pharmaceutical Inc Cell cycle control drugs for cancer. IPO in January 2006. |
United States | N/A |
|
|
|
Onyvax Ltd Whole-cell allogenic vaccines for cancer. Acquired by VaxOnco Inc. |
United Kingdom | N/A |
|
|
|
XTL Biopharmaceuticals PLC Monoclonal antibody and small molecule therapeutics for Hepatitis. IPO in September 2000. Fully disposed. |
United Kingdom | N/A |
|
|
|
Biowisdom Ltd Knowledge management software for drug development. |
United Kingdom | N/A |
|
|
|
VivoMedica PLC Advancing medical devices from prototype to market. Reversal in to AIM listed company in July 2005. |
United Kingdom | N/A |
|
|
|
De Novo Pharmaceuticals Ltd A world leader in in-silico structure-based drug design, de novo drug design. |
United Kingdom | N/A |
|
|
|
PanTherix Ltd A start-up biotech specializing in antibiotic target validation and drug discovery. |
United Kingdom | N/A |